Medicare pilot would pay ambulance agencies to stock critical drugs

What does this do?

HR 3443 launches a five-year test program in which Medicare pays ambulance agencies to stock and maintain critical medications and blood products, including epinephrine, albuterol, fentanyl, and blood products, even when a given patient is not on Medicare. At least one agency from each of the ten federal regions must participate, with representation from rural, suburban, and urban areas. The bill also directs MedPAC and federal health officials to study Medicare payments for emergency medical services and issue guidance on the problem of extended hospital wait times for paramedics.

Who does it affect?

Medicare patients who call 911, paramedics, EMTs, EMS agency directors, and hospital emergency departments are directly affected. Rural and underserved communities receive specific attention because ambulance agencies in those areas face the greatest challenges with medication shortages and staffing.

Why does it matter?

Current Medicare rules only pay for ambulance services actually used on a Medicare patient, leaving agencies without a funding mechanism to maintain adequate supply stockpiles during shortages. If the pilot leads to better-stocked ambulances and a more stable EMS workforce, the quality of emergency care could change for patients across coverage types.

What does it cost, and who pays?

Medicare would make payments to ambulance agencies to cover the cost of stocking and maintaining supplies under the pilot program. The bill does not specify total program spending or payment amounts.

Where does it stand?